These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 26597673)
1. Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. Lo Re V; Carbonari DM; Lewis JD; Forde KA; Goldberg DS; Reddy KR; Haynes K; Roy JA; Sha D; Marks AR; Schneider JL; Strom BL; Corley DA Am J Med; 2016 Mar; 129(3):283-91.e5. PubMed ID: 26597673 [TBL] [Abstract][Full Text] [Related]
2. Liver injury associated with ketoconazole: review of the published evidence. Greenblatt HK; Greenblatt DJ J Clin Pharmacol; 2014 Dec; 54(12):1321-9. PubMed ID: 25216238 [TBL] [Abstract][Full Text] [Related]
3. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. García Rodríguez LA; Duque A; Castellsague J; Pérez-Gutthann S; Stricker BH Br J Clin Pharmacol; 1999 Dec; 48(6):847-52. PubMed ID: 10594489 [TBL] [Abstract][Full Text] [Related]
4. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318 [TBL] [Abstract][Full Text] [Related]
5. The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes. Luo X; Li T; Yu Z; Xue X; Zhao H; Li N; Ma L; Yang C; Huang L; Feng W Xenobiotica; 2019 Jul; 49(7):753-761. PubMed ID: 29770723 [TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals. Beck KR; Telisman L; van Koppen CJ; Thompson GR; Odermatt A J Steroid Biochem Mol Biol; 2020 May; 199():105605. PubMed ID: 31982514 [TBL] [Abstract][Full Text] [Related]
7. Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study. Tang L; Yang XF; Qiao M; Zhang L; Tang XW; Qiu HY; Wu DP; Sun AN J Mycol Med; 2018 Jun; 28(2):379-383. PubMed ID: 29673771 [TBL] [Abstract][Full Text] [Related]
8. Risk of oral antifungal agent-induced liver injury in Taiwanese. Kao WY; Su CW; Huang YS; Chou YC; Chen YC; Chung WH; Hou MC; Lin HC; Lee FY; Wu JC Br J Clin Pharmacol; 2014 Jan; 77(1):180-9. PubMed ID: 23750489 [TBL] [Abstract][Full Text] [Related]
9. Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS. Luo X; Xue X; Li T; Zhang Y; Huang L; Cheng G Curr Drug Metab; 2020; 21(13):1022-1030. PubMed ID: 33092505 [TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy. Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723 [TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. Levin MD; den Hollander JG; van der Holt B; Rijnders BJ; van Vliet M; Sonneveld P; van Schaik RH J Antimicrob Chemother; 2007 Nov; 60(5):1104-7. PubMed ID: 17827141 [TBL] [Abstract][Full Text] [Related]
12. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Skiest DJ; Vazquez JA; Anstead GM; Graybill JR; Reynes J; Ward D; Hare R; Boparai N; Isaacs R Clin Infect Dis; 2007 Feb; 44(4):607-14. PubMed ID: 17243069 [TBL] [Abstract][Full Text] [Related]
14. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233 [TBL] [Abstract][Full Text] [Related]
16. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Gearhart MO Ann Pharmacother; 1994 Oct; 28(10):1177-81. PubMed ID: 7841574 [TBL] [Abstract][Full Text] [Related]
17. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Yu DT; Peterson JF; Seger DL; Gerth WC; Bates DW Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):755-67. PubMed ID: 15654717 [TBL] [Abstract][Full Text] [Related]
18. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). Gupta A; Unadkat JD; Mao Q J Pharm Sci; 2007 Dec; 96(12):3226-35. PubMed ID: 17518356 [TBL] [Abstract][Full Text] [Related]
19. Development of a liquid chromatography tandem mass spectrometry method for the simultaneous measurement of voriconazole, posaconazole and itraconazole. Wadsworth JM; Milan AM; Anson J; Davison AS Ann Clin Biochem; 2017 Nov; 54(6):686-695. PubMed ID: 27941128 [TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of tinea versicolor. Savin R J Fam Pract; 1996 Aug; 43(2):127-32. PubMed ID: 8708621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]